Bret Benton Ph.D. is Head of Clinical Microbiology at Boston Pharmaceuticals. Prior to joining Boston Pharmaceuticals Bret was a Senior Investigator at Novartis where he worked for 6 years leading the Clinical Microbiology group. Bret served as the lead microbiologist on multiple lead optimization projects as well as the monobactam LYS228 (now BOS-228) and TOBI®/TOBI® Podhaler™ (tobramycin) development programs. Prior to Novartis Bret led the Clinical Microbiology group at Theravance, with responsibility including the Phase 2 and Phase 3 microbiology development of Vibativ™ (telavancin). Bret earned his Ph.D. degree in Microbiology and Genetics from the State University of New York at Stony Brook and was an American Cancer Society Postdoctoral Research Fellow at UC Berkeley.